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AbstrACt
Objective To identify and critically synthesise definitions 
of acute flares in knee osteoarthritis (OA) reported in the 
medical literature.
Design Systematic review and narrative synthesis. We 
searched Medline, EMBASE, Web of science and six other 
electronic databases (inception to July 2017) for original 
articles and conference abstracts reporting a definition of 
acute flare (or synonym) in humans with knee OA. There 
were no restrictions by language or study design (apart 
from iatrogenic-induced flare-ups, eg, injection-induced). 
Data extraction comprised: definition, pain scale used, 
flare duration or withdrawal period, associated symptoms, 
definition rationale, terminology (eg, exacerbation or flare), 
baseline OA severity, age, gender, sample size and study 
design.
results Sixty-nine articles were included (46 flare design 
trials, 17 observational studies, 6 other designs; sample 
sizes: 15–6085). Domains used to define flares included: 
worsening of signs and symptoms (61 studies, 27 different 
measurement tools), specifically increased pain intensity; 
minimum pain threshold at baseline (44 studies); minimum 
duration (7 studies, range 8–48 hours); speed of onset (2 
studies, defined as ‘sudden’ or ‘quick’); requirement for 
increased medication (2 studies). No definitions included 
activity interference.
Conclusions The concept of OA flare appears in the 
medical literature but most often in the context of flare 
design trials (pain increases observed after stopping usual 
treatment). Key domains, used to define acute events in 
other chronic conditions, appear relevant to OA flare and 
could provide the basis for consensus on a single, agreed 
definition of ‘naturally occurring’ OA flares for research 
and clinical application.
PrOsPErO registration number CRD42014010169.
IntrODuCtIOn 
Recurrent acute events or episodes feature 
in the natural history of many chronic health 
conditions. The extent to which they charac-
terise the condition varies, as do the presumed 
pathophysiological mechanisms, and scien-
tific and lay terms used to describe them (eg, 
an acute exacerbation of chronic obstruc-
tive pulmonary disease (COPD) or asthma, 
an attack of gout or a rheumatoid arthritis 
flare). With recognition of their importance 
has come concerted effort to define these 
phenomena. Definitions for exacerbations 
or flares currently exist for COPD,1 2 asthma,3 
systemic lupus erythematosus (SLE)4 and 
ankylosing spondylitis (AS)5 and there are 
working groups currently trying to define 
these for rheumatoid arthritis,6–8 gout9 and 
atopic dermatitis/eczema.10 Despite the 
different language used, these definitions 
share some common, core domains: the onset 
or worsening of symptoms and signs above 
normal day-to-day variability; speed of onset; 
duration of sustained worsening and change 
in medication/healthcare usage.
Osteoarthritis (OA) appears to comprise 
multiple disease trajectories11–15 and 
symptom variability over time and the pres-
ence of intermittent pain is well-recognised.16 
Although OA does not typically have the 
same very obvious acute events as conditions 
like gout, flares in OA joints are encoun-
tered in practice, these phenomena appear 
in patient literature,17 have been discussed in 
expert reviews18 and are mentioned in ‘flare 
design’ trials in OA.19 These studies induce 
acute episodes of pain or flare-ups by asking 
patients to withdraw their usual medication.
In 2009, Marty et al proposed scoring 
criteria for knee OA flares based on nocturnal 
awakening, knee effusion, morning stiffness 
and limping,20 but it is unclear whether this 
has contributed to a common understanding, 
shared terminology and criteria. A common 
definition of OA flare could be important for 
a number of reasons: (i) to facilitate commu-
nication between researchers, (ii) to allow 
strengths and limitations of this study
 ► Identified key domains that are used to define acute 
events by undertaking a comprehensive synthesis of 
definitions used in the medical literature.
 ► Broad search strategy covering a wide range of da-
tabases including bibliography checks and confer-
ence abstracts.
 ► Prospectively registered with an international regis-
ter of systematic reviews (PROSPERO).
 ► Did not include potential synonyms as search terms 
(‘attack’, ‘episode’, ‘fluctuations’).
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more direct comparisons between studies on frequencies, 
determinants and course of events, (iii) to facilitate new 
insights into novel pathophysiological mechanisms and 
treatments through valid and homogenous case defini-
tions and (iv) to help clinicians with prompt diagnosis 
and management.
The aim of this systematic review was to explore the 
extent to which a concept of OA flare is reported in the 
medical literature and the prospects for a common, shared 
definition of these for research and clinical application.
MEthODs
This systematic review was registered with PROSPERO 
registration number CRD42014010169. The review 
protocol has not been published.
Literature sources and study selection
We searched electronic databases from inception to July 
2017; ASSIA, EMBASE, Web of Science, Health Manage-
ment Information Consortium (HMIC), SPORTDiscus, 
Medline, CINAHL, PsycINFO, AMED, Ageline, Cochrane 
Database of Systematic Reviews and Cochrane Controlled 
Clinical Trials (CENTRAL). The search was developed 
using previously piloted terms for knee OA and a liter-
ature search for common terms used to describe acute 
events. Searches used combined and/or truncated key 
terms including: (‘KNEE OSTEOARTHRITIS’ OR (knee 
N3 pain) OR (knee N3 arthrosis) OR (knee N3 joint) OR 
(knee N3 osteoarthritis)) AND (exacerbation OR flare 
OR (pain AND (diary OR diaries)) OR (pain N3 variab*) 
OR (pain N3 *) OR (pain N3 *) OR (pain N3 *) OR (pain 
N3 pattern$) OR (daily N3 pain)). A database search 
strategy is included in the online supplementary table 1. 
Reference lists of all included full-text articles retrieved 
for detailed examination were manually searched.
Studies were included in the final full-text peer-re-
view if they contained a description or definition of an 
acute exacerbation or flare-up of knee OA in human 
adults (aged 18 years or over) in the general popula-
tion, primary care or hospital settings. Studies were 
included even if their description was not based on clear 
measurement criteria (eg, stating a ‘significant increase 
in pain’ but not the amount of change on a pain score 
this would equate to). Studies that included a mixed OA 
population (eg, knee or hip OA) and did not separately 
report knee-specific findings were included. There were 
no restrictions on study dates or design. All non-English 
language articles were translated to identify a flare defini-
tion. Theses, dissertations, book chapters and guidelines 
and animal studies were excluded. Conference abstracts 
were included if they contained a definition for an OA 
flare-up. Studies were excluded if the flare was induced 
by an iatrogenic source, for example, injection-induced 
flares,21 as these may have been caused by a different 
pathophysiological process. Abstracts were included in 
this study as the main outcome of interest was the defi-
nition of flare used and it was decided that including 
abstracts would ensure a more comprehensive review. For 
each abstract, a search was conducted to identify a corre-
sponding full-text paper. Where one was found only the 
full paper was included in the review.
The search and article retrieval was conducted by the first 
reviewer (ELP). Articles were downloaded into RefWorks 
bibliography and database manager (RefWorks Copyright 
2009). Duplicates were removed and all titles were screened 
by ELP against inclusion criteria, with the first 20 titles 
checked by two reviewers (ELP and MJT) for consistency. 
For qualitative studies, all identified potentially eligible full-
text articles were obtained.
All abstracts and then full-text articles were screened 
by two reviewers (ELP and MJT), with disagreements 
resolved by consensus adjudicated by a third reviewer 
(GP). Where articles could not be retrieved or if the flare 
definition used was not included in the text, contact with 
authors was made.
The final included articles were checked to ensure results 
were not duplicated, for example, where different authors 
were reporting on the same dataset, to reduce bias.22 For 
articles containing pooled studies, the original studies were 
sought and included in the main analysis, where available. 
No full-text articles were required to be translated.
Data extraction
The following data pertaining to flares were extracted 
from full-text articles by the first reviewer: definition used 
for change in pain, pain scale used, duration of flare (for 
flare design trials we extracted the duration of the with-
drawal period for comparison), associated symptoms, 
rationale behind definition used, terminology used (eg, 
exacerbation or flare), baseline OA severity, age range, 
gender, geographical location, number of participants 
and study design. Missing data were described in the data 
extraction tables.
Quality assessment of included studies
Our aim was to identify and contrast definitions of 
flare-ups used in the literature. We were not concerned 
with the methodological rigour of the studies deriving, 
evaluating or applying those definitions. However, for 
studies presenting definitions we sought supporting state-
ments that gave the rationale for the definition.
Data analysis
A narrative synthesis was undertaken guided by the four-
stage process of Popay et al.22 23 This approach was 
chosen as it allowed the words and text in the defini-
tions to be synthesised to summarise findings.23 The 
initial data extracted were grouped into drug withdrawal 
studies (‘flare design’) and other studies. Frequencies 
of components included in definitions was tabulated, 
these included; terminology used, onset/worsening of 
symptoms; signs/symptoms above day-to-day variability/
minimum threshold; speed of onset of symptoms; dura-
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This initial tabulation helped identify similarities and 
differences and allowed themes to emerge. This was done 
with an inductive-type approach, where possible, that is, 
without an a priori assumption, and deductively acknowl-
edging that the reviewers were clinicians, that is, they had 
some background knowledge of the topic of interest. This 
allowed further examination of the differences of defini-
tions used in drug withdrawal and non-drug withdrawal 
study designs, and examination of key components of defi-
nitions used.
Patient and public involvement
There was no patient or public involvement in this study.
rEsuLts
study selection
The literature search yielded 2194 articles, of which 
786 were duplicates (figure 1). After title screening, 
336 abstracts were reviewed, 223 were not relevant for 
the study purpose. One hundred thirteen articles were 
examined in full, which resulted in a further 60 being 
excluded. The main reason for exclusion was no defini-
tion of flare-up reported in text (n=56). At this stage, a 
further 16 articles were identified from the reference lists 
of the retrieved full-text articles resulting in 69 included 
studies for synthesis.
study characteristics
Characteristics of the included studies are described in 
table 1.20 24–91 The number of participants in each study 
ranged from 15 to 6085.20 48 Knee OA was defined by clin-
ical and/or radiological criteria.
Twenty-one included mixed knee and hip OA 
groups.24 29 31 37–39 42 45–47 54 55 57–59 63 71 73 75 77 In total, 
46 publications used a drug withdrawal RCT 
design,24 26–32 34–43 45–53 55–64 73–77 88–91 4 of which 
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were pooled studies28 32 41 62 and 1 used a cohort 
drug withdrawal design33 (table 1). The remaining 
22 publications included 17 observational 
studies,20 25 44 54 65–67 70–72 78 80–85 3 RCTs,79 86 87 1 survey68 
and 1 qualitative interview study.69 Nine of the included 
studies were abstracts.25 44 62 63 72 78 80 81 83 Two abstracts 
were removed as the corresponding full-text article was 
available.69 92 Studies using pooled data or the same 
dataset were included if they used different definitions 
of OA flare.28 44 52 53 62 65 70 71 74
rationale given for flare definitions
Six of the included studies gave rationale for the defi-
nition used.20 54 56 69 85 86 None of the definitions was 
based on a consensus procedure. The studies by Marty 
et al20 and Scott-Lennox et al56 were the only ones that 
undertook empirical investigation of flare definitions. 
The study by Marty et al20 was the only study specifically 
designed to validate a diagnostic tool for knee OA flares. 
Potential factors associated with flare-ups were identified, 
for example, knee swelling and the authors used a logistic 
regression analysis to assign a weight to each of the 
items identified. A flare-up score was determined using a 
general practitioner database and this was then validated 
using a rheumatologist database. Pain was not included in 
the final model.
Scott-Lennox et al56 sought to test whether four measures 
for flare intensity (patient’s self-assessment of pain scores, 
physician’s assessment of pain scores, patient’s global OA 
assessment and physician’s global OA assessment) could 
be combined to form a reliable and valid index using 
data from an RCT using a confirmatory factor analysis. 
The authors produced three flare intensity groups (low, 
moderate and severe) and highlighted how these could 
be used to examine treatment effects.
Cibere et al86 outlined face validity checks. It was spec-
ified that the flare definition had been determined 
by study rheumatologists to be a clinically important 
change in the Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) score. The defi-
nition used by Murphy et al69 was informed by two 
studies,28 53 which used a drug withdrawal design and 
from the research team’s own experience. Ricci et al54 
used a combination of data-driven and clinical judge-
ment approaches to establish an agreed cut point. Parry 
et al based their definition on OA flare design studies 
and flare definitions used in other chronic disease such 
as back pain and COPD.
Flare definitions in drug withdrawal studies
Terminology used
The majority of publications using a drug with-
drawal design used the term ‘flare’ in their descrip-
tion24–30 32 33 36–43 45–49 51 53 55–64 74–77 88–91 (n=42; table 2).
One study used the term ‘flare-up’,52 two studies 
referred simply to ‘worsening of symptoms’31 50 and three 
studies used no specific label.34 35 73
Coverage of key components
Onset/worsening of symptoms and signs beyond normal-day-
to-day variability: forty-four studies included onset or 
worsening of signs and symptoms as part of their defini-
tion.24 26–32 34–41 43 45–53 55–64 73–75 77 88–91 All studies included 
increased pain intensity in their definition. A further 
two52 53 specified further signs and symptoms. These 
included swelling, inflammation, erythema, morning stiff-
ness and nocturnal pain. No studies quantified day-to-day 
variability.
Twenty-six measurement tools were used to define 
onset/worsening of symptoms and signs. The most 
commonly used tools were the Western Ontario and 
McMaster Universities Arthritis index (WOMAC) Q1 (pain 
on walking on flat surface) 100 mm Visual Analogue Scale 
(VAS) (n=9)29 30 32 38 41 45 59 73 75 and the Investigator Assess-
ment of Disease Status (n=11)28–30 38 40 45 59 73–75 77 (table 3). 
Thirty-four studies used only single-item measurement 
tools,27–30 32 34–43 45 47 48 50 52 55 56 58 59 61–63 73–77 90 91 five used 
multiitem31 46 51 53 60 and five used both single-item and 
multiitem tools.24 26 33 88 89
In addition, the format of global ratings appears to be 
variable as is use and reporting of the WOMAC.93 However, 
despite the exact format of reporting being inconsistent, 
in general, studies used single items in four areas—pain 
on activity, pain (not necessarily on activity), physician/
investigator global rating and patient global rating.
Temporal characteristics: none of the included drug 
withdrawal design studies reported a specific time for 
defining the speed of onset of symptoms. However, they 
did describe withdrawal or ‘washout’ periods, whereby 
after withdrawal of usual medication, participants were 
given a certain time frame in which to experience ‘flare’ 
symptoms in order that they were entered into the 
study. In total 30 of the studies specified a withdrawal 
period.27 30 31 33–36 38–40 43 45–52 56 58 60 61 64 73 74 76 77 88–90
Four studies specified a time period for minimum 
duration of symptoms, which ranged from 24 hours to 5 
days.52 53 55 57
Change in medication or healthcare usage: only one study 
used increase in medication as part of their definition; 
‘pain requiring supplemental analgesic medication and/
or an increase in non-steroidal anti-inflammatory drug 
dose’.57
Additional domains: thirty-six studies included a minimum 
threshold, which was usually a minimum level of pain that 
was required before the participant was considered to 
have a flare.24 26 28–31 33 35–38 40–43 45–47 51–53 55 56 58–63 73 75 76 88–91 
There was general concordance with the minimum 
thresholds that different measurement tools used with 
a few exceptions. A threshold of 40 mm on a 0–100 mm 
scale was used in 8 of 10 studies using the WOMAC VAS 
3.0 Q1 ‘pain on walking on a flat surface’29 30 38 41 45 59 73 75 
and 4 of 14 studies using the Patient Global Assessment 
of Disease Status.29 45 73 75 In studies using various forms 
of Investigator/Physician Global Assessment, the majority 
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or very poor’.29 30 45 73 The minimum threshold on the 
Lequesne index (0–10) was either 553 or 7.46 51 60
Flare definitions in non-withdrawal flare/discontinuation 
studies
Terminology used
‘Flare’ was the term most common used in non-with-
drawal design studies20 25 66 67 69 70 78–80 85 87 (n=11) (table 2). 
One study used the term ‘flare-up’,54 eight used ‘exac-
erbation’44 65 68 72 81–84 (five publications were from the 
same team) and one referred to both ‘exacerbation’ and 
‘flare’.71 None referred to ‘worsening of symptoms’ or did 
not use any specific label.
Coverage of key components
Onset/worsening of symptoms and signs beyond normal day-to-day 
variability: 16 of 22 studies used onset or worsening 
of symptoms in their definition.25 44 54 66 68 69 72 78 81–87 92 
Two studies did not use pain intensity as part of its defi-
nition.20 80 Three studies included symptoms other than 
pain in their definition.20 66 68 These included nocturnal 
awakenings, effusion, morning stiffness, night pain, 
limping and warmth.
The study by Murphy et al69 included an investigator 
definition of flare and sought to describe patient experi-
ence of flares through face-to-face individual interviews. 
Both investigator and patient definitions included onset/
worsening of symptoms and signs; however, there was no 
differentiation from day-to-day variability.
Seven studies used a measurement tool to define onset 
of signs and symptoms (table 3). These included the Pain 
NRS (0–10),25 54 65 78 85 WOMAC knee pain score VAS 
(0–500),72 pain walking on a flat surface (WOMAC),86 87 
Global Assessment of Disease Status (physician) (5-point 
Likert scale)86 87 and knee pain VAS not further specified 
(0–100).44 81–84
Temporal characteristics: only one study set a definition 
for speed of onset, describing this only as ‘sudden’ with 
no further specification.66 Patients in the study by Murphy 
et al used the terms ‘quick’ and ‘sudden’ to describe flare 
onset.69 Three studies specified a minimum duration of 
symptoms ranging from 8 to 48 hours.20 65 67 In the study 
by Murphy et al, patients described duration between 10 s 
and 15 min.69
Change in medication/healthcare usage: no studies used 
change is medication or healthcare usage as part of 
their definition. However, in the study by Murphy et al, 
patients reported either taking rest or using additional 
medication.69
Additional domains: two studies defined distribu-
tion-based minimum thresholds for flare as the highest 
30%72 or highest 33%73 of WOMAC Pain subscale scores 
among participants in the Longitudinal Examination of 
Arthritis Pain cohort (total score out of 50 was normalised 
to a 0–10 scale).
DIsCussIOn
Flares in OA are recognised in existing clinical guid-
ance94 and reviews,95 96 but typically merit little more 
than a passing mention. Our analysis of the definitions 
has resulted in the findings of common core domains, 
which will be useful for developing an agreed consensus 
Table 3 Summary of number and type of single-item and multiitem measurement tools used
Single-item scales:
Pain on activity: WOMAC Q1 3.0 VAS ‘pain on walking on a flat surface’ (0–100 mm) (n=11)
Pain on walking VAS (0–100 mm) (n=5)
Pain on movement VAS (0–100 mm); ambulatory pain (5-point Likert); pain with physical 
activity VAS 11-point scale (n=2)
Pain (not further specified): Pain VAS (0–100 mm) (n=15)
Patients assessment of pain score (0–10); pain scale (0–3); Pain NRS (0–10) (n=11)
Standing knee pain Item 5 WOMAC pain scale (n=1)
Global rating
(physician/investigator)
Investigator Assessment of Disease Status (n=11)
Physicians Global Assessment of Arthritis (n=6)
Physician Global Assessment of OA (n=2)
Physician Global Assessment of Disease Status (n=2); Investigator Assessed Pain Grade; 
(Physician) Overall Disease Activity (0–100); Physicians Pain Assessment (4-point LK) (n=3)
Global rating (patient) Patients Global Assessment of Arthritis (n=7)
Patient Global Assessment of OA (n=3)
Patient Global Assessment of Disease Status (n=4)
Multiple-item scales:
Lequesne OA Severity Index (n=5)
WOMAC LK3.1 (0–20) (n=3)
WOMAC LK Pain subscale (0–25); WOMAC OA Index Questionnaire (n=1); WOMAC knee pain 
score (0–500) [n=7]; KOFUS (0–14) (n=1)
KOFUS, Knee Osteoarthritis Flare-up Score; LK, Likert scale; N, number of included studies; OA, osteoarthritis; VAS, Visual Analogue Scale; 
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definition for OA flare. From a clinical perspective, a 
unified definition of a flare could enable clinicians to 
provide prompt, rationalised and focused treatment. 
This could also have implications for delivery of self-man-
agement strategies involving patients and how episodic 
management is advocated by clinical guidelines. Our 
review was motivated by an interest in seeking greater 
clarity on how these phenomena might be defined by 
undertaking a broad search strategy, noting that similar 
efforts have been pursued in other chronic diseases. While 
we found no current single, agreed definition of OA flare, 
our review of 69 published studies suggests a number of 
common domains, which may capture cardinal features. 
These were: onset/worsening of symptoms and signs, 
attainment of a minimum symptom threshold during 
flare, speed of onset/worsening and duration of elevated 
symptoms/signs. However, we found considerable varia-
tion in how these domains have been operationalised for 
measurement suggesting the need for further conceptual 
clarification and consensus.
Each potential cardinal feature of OA flare presents 
different challenges for achieving consensus. The goal 
of an agreed composite definition is to facilitate both 
reproducible and comparable research, while enabling 
more consistent recognition and identification of these 
phenomena in routine practice. The heterogeneity of OA 
should also be considered in any definition of a flare-up. 
Most studies included in our review required an increase 
in pain over ‘usual’ or ‘baseline’ intensity. Although this 
was measured using a wide range of measurement instru-
ments, several studies selected an increase of 2 or more 
points on a 0–10 scale providing a possible starting point 
for consensus. Yet this possible ‘signal’ is arguably diffi-
cult to interpret without also considering the amount 
of background ‘noise’, that is, within-person diurnal97 
and day-to-day variability,98 and the absolute level 
(‘minimum threshold’) of pain during a flare. There was 
general concurrence with the minimum threshold that 
was adopted, for example, 40 mm on a 0–100 mm scale 
and this may indicate the potential level of minimally 
important clinical difference. In the study by Marty et 
al, an increase in pain was not independently associated 
with flare-up after adjusting for other potential features.20 
However, the studies by Marty et al20 and Scott-Lennox et 
al56 were the only ones that had attempted to derive and/
or validate a prediction model for OA flares. Interestingly, 
their approaches have not been widely adopted which 
suggests the complexity of reaching a widely accepted 
model. Further research on detecting flares over with-
in-person ‘normal’ variability by collecting frequent 
repeated measures of pain intensity may be valuable but 
this approach would not be feasible when identifying 
flares presenting at the point of care in routine clinical 
practice. Instead, this may have to rely on the judgement 
of the patient and/or clinician, the approach used, for 
example, in defining exacerbations in COPD.1 A similar 
consideration surrounds the speed of onset, which was 
not well defined by studies in our review. Drug withdrawal 
design studies specified washout periods between 2 and 15 
days, but this is unlikely to be synonymous with speed of 
onset. The remaining studies used terms such as ‘sudden’ 
and ‘quick’. In COPD, for instance, a judgement around 
‘acute onset’ or ‘sudden onset’ appears to be acceptable 
for clinical recommendations, but we would add that the 
speed of onset of OA flares ought to be considered also 
in relation to underlying biologically plausible mecha-
nisms. Indeed, presumed aetiology has been argued as a 
useful feature in defining acute exacerbations in COPD.99 
Minimum duration ranged from 8 hours to 5 days in our 
review; however, this was not widely reported. COPD defi-
nitions refer to a ‘sustained worsening’ of symptoms,2 but 
does not appear to be a feature in other chronic diseases. 
A minimum duration in OA may help distinguish flares 
from day-to-day variability. Increase in medication was not 
found to be a key component in this review despite it being 
a feature in other chronic diseases such as AS,5 SLE,4 100 
inflammatory bowel disease and101 COPD.1 Interference 
with function did not emerge strongly from our review as 
a cardinal feature of OA flare. In other chronic musculo-
skeletal conditions, such as back pain, interference with 
function was not shown to be significantly associated with 
having a flare-up102 and this domain does not feature in 
the definitions of exacerbations or flares in diseases such 
as COPD,1 2 asthma,3 AS5 or SLE.4
Our review has several strengths and some weaknesses 
that deserve attention. We adopted a broad search 
strategy, covering a wide range of databases, and featuring 
bibliography checks, contact with authors, inclusion 
of conference abstracts, no language restrictions and 
a minimal threshold (any description or definition of 
flare) for inclusion. Five studies that were included in a 
similar review by Cross et al103 were not included in this 
study; four did not contain a clear definition of flare-up, 
including one which gave a definition of knee OA progres-
sion and the final paper by Sands et al104 was not in our 
search but the original study was.58 We did not, however, 
search the grey literature and we did not include some 
potential synonyms as search terms (‘attack’, ‘episode’, 
‘fluctuations’), although these terms appeared often 
to relate to comorbidities and other phenomena (eg, 
episodes of care) and would therefore have been a less 
efficient search strategy than relying on snowball refer-
ences. Data extraction was performed by only a single 
reviewer. Nevertheless, we argue that our review provides 
a reasonably comprehensive summary of how ‘flares’ in 
OA have been described and defined in the medical liter-
ature. In comparison with the study by Cross et al,103 our 
search strategy appeared comprehensive yet efficient—
returning 69 included articles compared with 23. We feel 
that our review expands on the findings of the review by 
Cross et al and adds strength to this important area. The 
majority of studies describe experimental ‘flare design’ 
trials in which flares are induced by drug withdrawal prior 
to enrolment and randomisation. While intentional or 
unintentional reduction in usual analgesia may indeed 
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should not be assumed to represent ‘naturally occurring’ 
flares. Flare design trials, for example, are unlikely to 
capture change in management or healthcare usage that 
may be a common consequence of OA flares—something 
that is included in flare definitions in other conditions 
such as AS,5 SLE,4 100 inflammatory bowel disease101 and 
COPD.1
A systematic review such as this cannot hope to resolve 
the need for a common conception and definition of 
flares in OA. Definitions for exacerbations of disease 
states are generally reached through a long process of 
consensus exercises involving key stakeholders, experts 
and patients in addition to appraisal of relevant literature 
from studies using multiple methods.6 8 105 However, we 
believe that a consensus definition that is reliable, valid 
and feasible and widely acceptable both clinically and for 
research purposes should now be sought. The cardinal 
features described in this review; onset/worsening of 
symptoms and signs, attainment of a minimum symptom 
threshold during flare, speed of onset/worsening and 
duration of elevated symptoms/signs could help start 
this discussion. Furthermore, observational studies with 
repeated measures could give an important insight into 
the nature of these phenomena.
COnCLusIOn
A broad range of ad hoc definitions currently exist in 
the medical literature. The majority are from drug with-
drawal or flare-induced trials rather than ‘naturally’ 
occurring flares. The cardinal feature is pain inten-
sity with minimum symptom threshold being another 
important feature. This review has identified the need to 
gain consensus on a common definition that can be used 
for research and clinical application.
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